Table 2.
Clinicopathological characteristics and survival of patients with CCRCC and Xp11.2 RCC treated with different surgical methods
| CCRCC (n=32) | Xp11.2 RCC (n=22) | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| RN group (n=12) | TE group (n=20) | P | RN group (n=19) | RN in small group (n=14) | Pa | |
| Age: mean ± SE (range, years) | 70.2±2.8 (51~81) | 54.2±2.1 (40~69) | <0.001 | 24.1±2.5 (3~40) | 23.1±2.9 (3~40) | <0.001 |
| Tumor diameter: mean ± SE (range, cm) | 4.78±0.28 (3.2~6.2) | 3.22±0.24 (2.2~5.5) | <0.001 | 5.50±0.50 (3~10) | 4.35±0.27 (3~6) | 0.215 |
| Stage (I/II/III/IV) | 9/0/1/2 | 18/0/0/2 | 0.395 | 11/1/4/3 | 11/0/2/1 | 0.911 |
| Pseudocapsule incidence (%) | 12/12 (100%) | 20/20 (100%) | 1.000 | 11/19 (57.9%) | 10/14 (71.4%) | 0.012 |
| Pseudocapsule integrity rate (%) | 5/12 (41.7%) | 18/20 (90%) | 0.006 | 7/11 (63.6%) | 6/10 (60%) | 0.292 |
| Median follow-up time (range, months) | 39.5 (14~70) | 36.5 (7~71) | 0.795 | 39 (5~85) | 45.5 (5~85) | 0.820 |
| 3-year progression-free survival rate (%) | 77% | 85% | 0.733 | 86% | 100% | 0.931 |
| 5-year progression-free survival rate (%) | 77% | 66% | 0.733 | 72% | 82% | 0.931 |
| 3-year overall survival rate (%) | 86% | 92% | 0.845 | 84% | 100% | 0.567 |
| 5-year overall survival rate (%) | 86% | 81% | 0.845 | 65% | 71% | 0.567 |
Xp11.2 RCC, renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion; CCRCC, clear cell renal cell carcinoma; RN, radical nephrectomy; TE, tumor enucleation; SE, standard error.
a
P value concerning comparison between 19 Xp11.2 RCC and 12 CCRCC treated by RN.